📖
Efficacy and safety of immune checkpoint inhibitor plus bevacizumab-based chemotherapy in advanced or recurrent KRAS-mutant non-squamous NSCLC: the SPIRAL-STONE study.
Ishida M, Yamada T, Kamada R, Hibino M, Egami M, Nakano T, Imabayashi T, Takumi C, Ishida K, Takeshita M, Masubuchi K, Izumi M, Ota T, Morito S, Chihara Y, Hirai S, Shiotsu S, Sawada R, Kawachi H, Nishioka N, Iwasaku M, Takayama K

Efficacy and safety of immune checkpoint inhibitor plus bevacizumab-based chemotherapy in advanced or recurrent KRAS-mutant non-squamous NSCLC: the SPIRAL-STONE study.

Medicine & Health Published 2026 Verification Pending

Overview & Synopsis

Open access biomedical research article published in Front Immunol.

Indexed from repository: PubMed Central (pmc.ncbi.nlm.nih.gov)
Loading document from verified source...
Keyboard Shortcuts: ← / → for pages • + / - for zoom • 0 to fit width Powered by Mozilla PDF.js v3.11

Document Information

Document Title Efficacy and safety of immune checkpoint inhibitor plus bevacizumab-based chemotherapy in advanced or recurrent KRAS-mutant non-squamous NSCLC: the SPIRAL-STONE study.
Author / Organization Ishida M, Yamada T, Kamada R, Hibino M, Egami M, Nakano T, Imabayashi T, Takumi C, Ishida K, Takeshita M, Masubuchi K, Izumi M, Ota T, Morito S, Chihara Y, Hirai S, Shiotsu S, Sawada R, Kawachi H, Nishioka N, Iwasaku M, Takayama K
Subject & Discipline Front Immunol
Categories Medicine & Health
Publication Year 2026
License / Rights Open Access / Creative Commons
Resource Verification Listed PDF (Verification Pending)
Original Host Website PubMed Central (pmc.ncbi.nlm.nih.gov)
File Format application/pdf (Portable Document Format)
Language EN
Catalog ID DOC-120592
Original Source Link Visit Source Page on pmc.ncbi.nlm.nih.gov »